Los Angeles, CA-based Sensydia, a non-invasive cardiac assessment company, has raised $8 million in funding. The investment round was led by Orlando Health Ventures, with participation from Colle Capital, Frontier Venture Capital, and others. Erick Hawkins, Chief Administrative Officer for Orlando Health, will join the Sensydia board of directors in conjunction with the financing.
The company plans to use the funds to finalize the development of the Cardiac Performance System (CPS) platform and submit it to the United States Food and Drug Administration (FDA) in 2024 for prioritized review as part of the FDA Breakthrough Devices Program.
Under the leadership of Anthony Arnold, President and CEO, Sensydia aims to broaden access to cardiac performance assessment beyond the hospital’s catheterization lab through its non-invasive CPS. The platform provides accurate, non-invasive evaluations of cardiac performance (cardiac output, ejection fraction, and pulmonary pressures) in under 5 minutes almost anywhere. Proprietary waveform machine learning methods used by CPS have been trained using gold-standard measurements from in-hospital catheterization lab data.
In 2018, Sensydia received FDA 510(k) clearance for non-invasive measurement of ejection fraction by CPS, and in 2022, the Sensydia CPS was granted Breakthrough Device Designation by the FDA.
